2 | | 2025 | | 7 | | | | --- | --- | --- | --- | --- | --- | | 日期 | | 年 | | | | | | | | 月 | | | | | | | | 12 | | | | | | | | 日 | 3 1 编号：2025-011 投资者关 系活动类 别 ◻️特定对象调研◻️分析师会议 ☑媒体采访◻️业绩说明会 ◻️新闻发布会◻️路演活动 ◻️现场参观☑电话会议 ◻️其他（请文字说明其他活动内容） 参与单位 财联社任健、黄立 长城证券：金瑞、陈逸同 浙江大学：李佳 紫杰基金：张醒 汉泽基金：胡玮 华安证券：来祚豪 中金公司：童宇琴 格隆汇：庞明明 垒土投资：葛晨曦 海峡资本：王干义 千日红私募：汤琎哲 开源证券：罗悦 中银资管：李倩倩 乐苍投资：谢桂 嘉世基金：周盘奇、李其东 中泰证券：王欣悦 鸿竹资产：费征帅 明澄投资：张宇博、侯子骄 千习资本：斯志坚 长城基金：储雯玉 赛维投资：吕政和 银河证券：石金漫、张渌荻 民生证券：周晓萌 东北证券：刘云坤、刘俊奇 高竹基金：李心宇 国海证券：张钰莹 善成投资：卫芳 安禅私募：钱曙和 诚通证券：沈燕萍 橡果资 ...

中国创新药获批数量进一步爆发。国家药监局最新统计显示，我国上半年批准创新药43个，中国创新药产业发展正在迎来DeepSeek一刻。 目前，全球巨头都在竞相开发下一代GLP-1类减重药，中国的候选创新药物成为跨国制药公司瞄准的目标。 6月2日，翰森制药与再生元（Regeneron）达成一项重磅许可协议，翰森将其在研的GLP-1/GIP双受体激动剂HS-20094的大中华区以外全球独占许可权利授 予再生元。 3月24日，联邦制药宣布将GLP-1/GIP/GCG三重受体激动剂UBT251的大中华区外全球权益授权给诺和诺德，交易规模高达20亿美元。 1月10日，先为达生物宣布与Verdiva Bio达成在除大中华区及韩国以外的全球开发和商业化许可与合作协议，合作的管线包括口服伊诺格鲁肽、口服胰淀素 受体激动剂、皮下注射胰淀素受体激动剂。根据协议，先为达生物将获得近7000万美元的首付款，最高达24亿美元的潜在开发、注册和商业化里程碑付款， 以及产品商业化后的分层销售额提成。 今年上半年，中国创新药对外授权步伐加速，迎来了生物医药的DeepSeek一刻。据安永的数据显示，上半年，中国公司与美国和欧洲合作伙伴之间达成的 ...

Core Viewpoint - Firefly Aerospace, a Texas-based startup known for successfully landing a robotic spacecraft on the moon, has filed for an initial public offering (IPO) with the SEC, aiming to list on the Nasdaq under the ticker "FLY" [1] Group 1: Company Overview - Firefly Aerospace specializes in small to medium-sized launch vehicles, lunar landers, and orbital space tugs, targeting payloads in the 1-10 ton range and NASA's Commercial Lunar Payload Services (CLPS) missions [2][3] - The company was founded in 2014 and underwent restructuring in 2017 to focus on commercial launches and deep space cargo [2] Group 2: Recent Developments - In November of last year, Firefly completed a $175 million funding round led by RPM Ventures, achieving a valuation of over $2 billion [2] - In May of this year, Northrop Grumman, a major defense contractor, announced an investment of approximately $50 million in Firefly [2] Group 3: Competitive Landscape - Firefly Aerospace aims to create a comprehensive ecosystem of small to medium rockets, lunar cargo transport, and in-orbit tugs, positioning itself in a niche that complements NASA's and U.S. government agencies' needs rather than directly competing with SpaceX's heavy-lift capabilities [3] - The company has secured multiple CLPS contracts from NASA, with individual contract values potentially reaching hundreds of millions of dollars [2]

每经记者｜许立波 每经编辑｜文多 2025年以来，创新药板块强势突围，成为成长赛道中的最大"黑马"。Wind数据显示，截至7月9日，全市场成立满一年的963只ETF中，仅有7只实现业绩翻 倍，港股创新药ETF（513120）便是其中之一，该基金近一年来的收益率达到103%（截至7月11日）。 从产业角度看，随着近年来全球医药巨头加快在华"扫货"的节奏，我国生物技术（Biotech）企业的BD（商务拓展）交易不断升温。同时，资本市场也有显 著回暖，特别是赴港上市的创新药企增加，标志着本土原研药在全球市场中的影响力持续上升。 在这场浪潮中，法律与合规成为各类交易背后的支点。从交易框架的制定、IP（知识产权）的归属到跨境交易的合规性，每一处都暗藏复杂博弈。对于大多 数仍处于临床阶段的中国生物技术公司而言，面对跨国药企的严苛标准，要如何在谈判桌上守住主动权并最终将自己的核心产品卖出好价，已成为当下最关 键的现实课题。 "每家企业所处的治疗领域、产品类型、临床开发路径都可能千差万别，而规则本身是一种抽象、概括性的制度设计，不可能覆盖所有具体情况。"刘毅铭强 调。 此前，曾有一家Biotech企业计划赴港上市，其技术平台 ...

🚨 NEW: Tether will end $USD₮ support on Omni, Bitcoin Cash SLP, Kusama, EOS, and Algorand by September 1, 2025, as part of its infrastructure review. https://t.co/Sjj1K29432 ...

Core Insights - The last analysis on Coca-Cola Company (NYSE: KO) was published in July 2024, focusing on its Q2 performance and strategic positioning [1] - The research emphasizes providing actionable investment ideas based on independent analysis [1] Investment Performance - The service has reportedly helped members outperform the S&P 500 and avoid significant losses during periods of high volatility in both equity and bond markets [2] - A trial membership is offered to assess the effectiveness of the investment strategy [2]

今年以来，中国人民银行坚持支持性的政策立场，实施适度宽松的货币政策，灵活运用各类总量和结构 性政策工具，保持金融市场整体运行平稳。目前政策工具箱储备充足，下半年，央行仍将根据内外部经 济形势择机施策，灵活把握政策力度与节奏。 "适度宽松"的货币政策，既要"宽松"，也要"适度"。回顾今年以来的货币政策施策，每一阶段都体现出 央行根据国内外经济金融形势和金融市场运行情况灵活应对。 今年年初，债券市场过度"抢跑"货币宽松预期，导致国债收益率快速下行；同时，美元走强对非美货币 形成压力，人民币汇率贬值压力凸显。彼时防空转、稳汇率优先级较高，央行通过暂停国债买卖操作、 适度收紧货币总闸门等措施，引导市场修正预期。同时，央行及时启用跨境融资宏观审慎调节参数、离 岸人民币央行票据等多项外汇管理工具，防范汇率超调风险。 "通过促进信贷均衡投放、治理和防范资金空转、整顿手工补息等措施，前期一些不合理的、容易消减 货币政策传导的市场行为得到治理，货币政策传导路径有望更加通畅。"浙商证券（601878）宏观联席 首席分析师廖博对证券时报记者表示，近期存款向理财分流的情况已有所弱化，也对广义货币(M_[2]) 余额增速上行有所支撑。 ...

Core Viewpoint - The successful trial production of the 200,000 tons/year mixed plastic waste resource utilization project by Dongyue Chemical in Guangdong marks a significant advancement in the chemical recycling of waste plastics, establishing a new industrial path for high-value and harmless utilization of waste plastics [1][9]. Industry Development - The establishment of the world's first industrialized waste plastic recycling facility in Guangdong exemplifies the province's efforts to extend the chemical product chain in the petrochemical industry [2][4]. - The petrochemical industry in Guangdong is undergoing a transformation from a focus on refining to driving new chemical materials, with integrated refining and chemical production becoming a core strategy for provinces competing for industrial dominance [3][10]. Market Dynamics - Major petrochemical companies are increasingly investing in Guangdong, enhancing the completeness of the petrochemical industry chain, which is characterized by large-scale projects and significant infrastructure investments [3][5]. - Guangdong aims to exceed a petrochemical industry scale of 2 trillion yuan by 2025, with a focus on creating a leading and world-class green petrochemical industry cluster [6][10]. Technological Innovation - The Dongyue Chemical project utilizes a unique "one-step" process for deep catalytic cracking of mixed waste plastics, achieving a product yield of over 92% without the need for complex sorting of low-value plastics [9][12]. - The project is positioned as a key initiative in the green chemical sector, contributing to sustainable development and the dual carbon strategy [9][13]. Strategic Positioning - Guangdong's petrochemical industry is characterized by a highly concentrated and integrated layout, with a strategic focus on developing a circular economy that connects upstream raw materials with downstream processing [7][13]. - The province's unique geographical advantages and advanced technological equipment position it as a central hub for the global chemical industry transition [10][14]. Future Outlook - The industry is expected to face challenges such as the need for increased self-sufficiency in high-end chemical materials and the pressure to reduce oil output while increasing the production of high-end chemical products [11][14]. - The focus will be on accelerating the transformation of refining and chemical integration, responding to the growing market demand from emerging industries like electric vehicles [11][13].

Core Viewpoint - The CRO (Contract Research Organization) sector is experiencing a significant upward trend, driven by the strong performance forecast of WuXi AppTec, which is expected to see substantial revenue and profit growth in the first half of 2025 [1][3]. Financial Performance - WuXi AppTec anticipates revenue of approximately RMB 20.8 billion for the first half of 2025, representing a year-on-year increase of about 20.6% [3]. - The company expects a net profit attributable to shareholders of around RMB 8.56 billion, reflecting a year-on-year growth of approximately 101.9%, which includes investment income from the sale of equity in an associate [3]. - The adjusted Non-IFRS net profit is projected to be about RMB 6.31 billion, up 44.4% year-on-year, while the net profit excluding non-recurring items is expected to be around RMB 5.58 billion, a 26.5% increase [3]. Business Segments - The chemical business remains the primary revenue source for WuXi AppTec, accounting for over 70% of total revenue in recent years [4]. - The company has successfully supported the approval of multiple new drugs by the FDA and other regulatory bodies, indicating strong performance in its chemical business [4]. - The GLP-1 (glucagon-like peptide-1) drug development area is highlighted as a significant growth opportunity, with the number of clinical candidates increasing substantially [5]. Industry Trends - The Chinese pharmaceutical industry is transitioning from generic drug production to innovative drug development, which is driving demand for CRO services [2][6]. - The total licensing-out transaction amount for innovative drug companies reached USD 45.5 billion in the first five months of the year, nearing the total for the previous year [6]. - The regulatory environment is supportive of innovative drug development, with new measures introduced to enhance the quality of innovation in the pharmaceutical sector [6]. Strategic Moves - WuXi AppTec is optimizing its CGT (cell and gene therapy) business by divesting certain assets to mitigate potential risks associated with regulatory changes [7]. - The global cell and gene therapy market is projected to grow significantly, indicating a favorable environment for WuXi AppTec's strategic focus in this area [7]. Market Dynamics - The CRO sector is expected to benefit from a rebound in investment and financing within the healthcare sector, with a notable increase in financing events and amounts [8]. - However, the industry faces intense competition, with the number of qualified clinical trial institutions in China increasing significantly, leading to price pressures [8]. - Despite challenges, the demand for medical outsourcing services is recovering, and companies with global service capabilities are well-positioned to capitalize on this trend [8].

Group 1 - The article emphasizes a commitment to focus on retired investors and those nearing retirement, aiming to help them maximize income from their investments [1] - The platform offers in-depth research on various income alternatives including REITs, mREITs, Preferreds, BDCs, MLPs, and ETFs [1] Group 2 - The article does not provide specific financial data or performance metrics related to any companies or sectors [2][3]